CollectionsMerck
IN THE NEWS

Merck

NEWS
September 4, 2013 | By Bonnie L. Cook, Inquirer Staff Writer
Ronald L. Stewart, 77, of Blue Bell, a senior business executive and leader in the pharmaceutical industry for 34 years, died of a heart arrhythmia Monday, Aug. 26, at his vacation home on Martha's Vineyard. His family said Mr. Stewart died in his sleep. He had not been ill. Mr. Stewart retired in 1999 from Merck, a global pharmaceutical manufacturer. At that time, he was executive director in charge of long-term care, marketing, and sales. Before joining Merck, Stewart worked for 24 years at SmithKline Beecham - now GlaxoSmithKline - in Philadelphia; he held positions in marketing, national accounts, government affairs, and human resources; he rose to vice president of corporate accounts.
BUSINESS
August 1, 2013 | By David Sell, Inquirer Staff Writer
Drugmaker Merck & Co. said Tuesday that its second-quarter revenue declined from $12.3 billion to $11 billion and its net income fell from $1.8 billion to $906 million compared with the same period in 2012. Merck, which is based in Whitehouse Station, N.J., has a big operation in West Point, Montgomery County, and other facilities in Pennsylvania and New Jersey. Some financial analysts have urged Merck to sell its consumer products division or its animal health unit. Merck, Pfizer, and Johnson & Johnson are the three drugmakers among the 30 companies in the Dow Jones Industrial Average.
BUSINESS
July 5, 2013 | By David Sell, Inquirer Staff Writer
Merck & Co., said Wednesday that it was recalling one lot of its hepatitis B vaccine Recombivax HB that was made in West Point, Montgomery County, because of fears that some of the vials could have cracked. The U.S. Food and Drug Administration posted a notice of the voluntary recall on its website. The medication is delivered via injection. "Merck's investigation concluded that for certain vials in the affected lot, the potential exists for a crack to have occurred in the vial," the FDA said in its statement.
BUSINESS
June 29, 2013 | By David Sell, Inquirer Staff Writer
Drugmaker Merck & Co. Inc. has agreed to sell manufacturing and related sites and options on several products to Aspen Pharmacare Holdings for about $1 billion, the largest divestiture for Merck since 2009. The manufacturing sites, employing about 960 people, are in the Netherlands. Merck facilities in Sioux City, Iowa, and Des Plaines, Ill., employ a total of 20 people and also will shift to Aspen. The 11 products had $248 million in 2012 sales, mostly in Latin America and East Asia.
BUSINESS
June 4, 2013 | By Steve Rothwell, Associated Press
NEW YORK - For now, bad news is good for the stock market. On Monday, investors judged that the latest weak economic reports would make it more likely that the Federal Reserve would continue to stimulate the economy and support a rally on Wall Street. The Institute for Supply Management (ISM) reported Monday that its factory index, a measure of U.S. manufacturing, fell in May to its lowest level since June 2009 as overseas economies slumped and weak business spending reduced new orders to factories.
BUSINESS
May 26, 2013
When Merck & Co. Inc. announced earlier this month that it planned to buy back $15 billion in common stock, it seemed likely that the move would follow the typical pattern: big talk, but little actual repurchase activity for months, if not years. Then the pharmaceutical company, with major operations in Montgomery County, struck an accelerated share-repurchase program with Goldman, Sachs & Co. last week to buy about $5 billion worth of Merck common stock. Also, Merck agreed to sell $6.5 billion in debt to raise cash to buy more shares, putting it well on the way to repurchasing shares worth $7.5 billion within the next 12 months.
BUSINESS
May 11, 2013 | By David Sell, Inquirer Staff Writer
Multinational drug companies, like other businesses, see Africa as an emerging market with tremendous opportunities and challenges, and that was a backdrop to Thursday's announcements of two programs designed to deliver more medicine and better health care to the continent. Merck & Co. and GlaxoSmithKline Plc joined the GAVI alliance in announcing from Cape Town, South Africa, an agreement to supply human papillomavirus (HPV) vaccine at lower prices to developing countries to help girls and women in those nations avoid cervical cancer.
BUSINESS
May 11, 2013 | Associated Press
NEW YORK - A Merck & Co. sales representative is suing the drugmaker for at least $100 million, saying it does not give women equal opportunities for advancement and punishes employees for maternity leave. Kelli Smith, who has worked at Merck since 2004, says in the lawsuit that the company's sales plans create incentives to discriminate against women, that women are discouraged from advancing their careers and are told they have to choose between being mothers and taking bigger roles at the company, and that men get more opportunities to meet senior managers and develop important contacts.
BUSINESS
May 3, 2013 | By David Sell, Inquirer Staff Writer
The 2,000 or so union employees and management at the Merck & Co. plant in West Point, Montgomery County, agreed to continue working and negotiating after the union contract expired Tuesday night. Weeks of negotiations and news of weak first-quarter financial results make the prospects for a new agreement and more job cuts - union or otherwise - unclear. On Wednesday, Merck said revenue and profits were down for the first quarter, and it lowered the profit expectations for the rest of 2013.
BUSINESS
April 7, 2013 | By David Sell, Inquirer Staff Writer
PRINCETON - Merck & Co.'s chief executive officer, Ken Frazier, says the drugmaker's facility in West Point, Montgomery County, is in no danger of being closed now. Merck is among the many pharmaceutical companies that have announced in recent months plans to close or consolidate facilities in hopes of squeezing more efficiency out of their operations. Some of those decisions involved laying off employees. Is West Point safe? "Yes," Frazier said Thursday evening after speaking about Merck's worldwide vaccine programs at Princeton University's Woodrow Wilson School of Public and International Affairs.
« Prev | 1 | 2 | 3 | 4 | 5 | Next »
|
|
|
|
|